	US 11,701,341 B2
	Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
Alastair MacKinnon, London (GB); and Jacqueline Parkin, London (GB)
Assigned to MEREO BIOPHARMA 1 LIMITED, London (GB)
Appl. No. 15/733,212
Filed by MEREO BIOPHARMA 1 LIMITED, London (GB)
PCT Filed Dec. 11, 2018, PCT No. PCT/GB2018/053590 § 371(c)(1), (2) Date Jun. 10, 2020, PCT Pub. No. WO2019/116021, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 1720622 (GB), filed on Dec. 11, 2017; and application No. 1802354 (GB), filed on Feb. 13, 2018.
Prior Publication US 2020/0352909 A1, Nov. 12, 2020
Int. Cl. A61K 31/415 (2006.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/415 (2013.01) [A61P 11/00 (2018.01); A61K 9/0053 (2013.01)]

10 Claims

1. A method for the treatment of AECOPD in a human patient having <2% blood eosinophils, comprising administering to a human patient in need thereof three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N -cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, solvate or hydrate thereof over a period of not longer than 7 consecutive days with at least one day between every dose.